Ameen Ali

Every diagnosis begins with a question. AI-powered genomic and phenotypic analysis helps clinicians find answers – faster. FDNA’s next-generation phenotyping (NGP) technologies are used by 70% of the world’s clinical geneticists across 10,000 sites in more than 130 countries. Our tools capture, structure, and analyze complex physiological and other clinical data to support more informed genomic evaluations. FDNA’s database includes an unprecedented depth of phenotypic and genotypic information associated with thousands of rare genetic diseases and health conditions, crowdsourced from real-world patient cases through our broad network of credentialed users. While our origins are in facial analysis, our future lies in the full spectrum of the phenotype. As a leader in AI-powered clinical decision support, FDNA is committed to delivering technologies that assist clinicians, researchers, laboratories and partners in advancing rare disease understanding and care. Since 2011, we have helped ease the diagnostic journey for many of the millions affected by genetic conditions—by empowering those dedicated to finding answers.